Human papillomavirus vaccine effectiveness within a cervical cancer screening programme: cohort study.
Adult
Cervix Uteri
/ virology
Early Detection of Cancer
/ statistics & numerical data
Female
Humans
Immunization Programs
/ statistics & numerical data
Italy
Logistic Models
Middle Aged
Papillomavirus Infections
/ prevention & control
Papillomavirus Vaccines
/ therapeutic use
Retrospective Studies
Treatment Outcome
Uterine Cervical Neoplasms
/ prevention & control
Cervical screening
human papillomavirus
vaccine
Journal
BJOG : an international journal of obstetrics and gynaecology
ISSN: 1471-0528
Titre abrégé: BJOG
Pays: England
ID NLM: 100935741
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
accepted:
13
07
2020
pubmed:
12
8
2020
medline:
20
1
2021
entrez:
12
8
2020
Statut:
ppublish
Résumé
To assess the effectiveness of an HPV vaccination programme in reducing the risk of cervical abnormalities identified at subsequent screening. Retrospective cohort study using administrative health data. General population of Ferrara Province, Italy. Female residents born in 1986-1993 and participating in the organized cervical screening programme in 2011-2018, who were eligible for HPV vaccination in catch-up cohorts. Logistic regression to evaluate the potential association between abnormal cervical cytology and one, two, three or at least one dose of HPV vaccine. Cervical abnormalities, as predicted by low-grade or high-grade cytology, by number of vaccine doses, stratified by age. The sample consisted of 7785 women (mean age 27.5 years, SD 2.3). Overall, 391 (5.0%) were vaccinated with ≥1 dose and 893 (11.5%) had abnormal cytology. Women receiving at least one vaccine dose were significantly less likely to have an abnormal cytology (adjusted odds ratio 0.52; 95% confidence interval 0.34-0.79). Similar results were observed for women receiving a single dose, for both bivalent and quadrivalent vaccines, and applying buffer periods (excluding cytological outcomes within 1 month, 6 months and 1 year of the first dose). In the context of an organised cervical screening programme in Italy, catch-up HPV vaccination almost halved the risk of cytological abnormalities. Among Ferrara women, vaccination against human papillomavirus halved the risk of screening cervical abnormalities.
Identifiants
pubmed: 32779381
doi: 10.1111/1471-0528.16429
doi:
Substances chimiques
Papillomavirus Vaccines
0
Types de publication
Evaluation Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
532-539Informations de copyright
© 2020 Royal College of Obstetricians and Gynaecologists.
Références
Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, et al. A review of human carcinogens - Part B: biological agents. Lancet Oncol 2009;10:321-2.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424.
Peirson L, Fitzpatrick-Lewis D, Ciliska D, Warren R. Screening for cervical cancer: a systematic review and meta-analysis. Syst Rev 2013;2:35.
Drolet M, Benard E, Perez N, Brisson M. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet 2019;74:590-2.
Palmer T, Wallace L, Pollock KG, Cuschieri K, Robertson C, Kavanagh K, et al. Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland: retrospective population study. BMJ 2019;365:l1161.
Ronco G, Segnan N, Giordano L, Pilutti S, Senore C, Ponti A, et al. Interaction of spontaneous and organised screening for cervical cancer in Turin, Italy. Eur J Cancer 1997;33:1262-7.
National Screening Observatory, Italian Cervical Carcinoma Screening Group. [Consensus Conference for the definition of the cervical carcinoma screening pathway in women vaccinated against HPV]. 2016.
Emilia-Romagna Region. [Diagnostic therapeutic protocol for screening for the prevention of cervical cancer in the Emilia-Romagna Region]. Fifth edn. Bologna; 2014.
Gardasil quadrivalent human papillomavirus (types 6, 11, 16, 18) vaccine, recombinant [package insert]. Whitehouse Station, NJ: Merck & Co. Inc.; 2006. https://www.merck.com/product/usa/pi_circulars/g/gardasil/gardasil_pi.pdf. Accessed 8 July 2019.
GSK Cervarix Summary of Product Characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000721/WC500024632.pdf. Accessed 8 July 2019.
Emilia-Romagna Region General Direction for Cures Health and Welfare. 2019 Health Profile - Emilia-Romagna Region; 2019.
De Togni A. Ferrara Health Agency. [Health profile of the Ferrara community - December 2018 data]; 2019. Accessed 27 March 2019.
Pascucci MG. HPV vaccines offer and uptake in Italy. National Conference of the Italian Group for Cervical Cancer Screening. Riccione; 2019.
Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002;287:2114-9.
ISTAT. National Statistics Institute Resident Population on 1 January 2018. Demographic Statistics [cited 8 July 2019]. Available from: http://demo.istat.it/
Woodman CB, Collins SI, Young LS. The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer 2007;7:11-22.
Winer RL, Kiviat NB, Hughes JP, Adam DE, Lee SK, Kuypers JM, et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis 2005;191:731-8.
Drolet M, Lemieux-Mellouki P, Mondor M, Fournier A, Markowitz L, Brotherton J, et al. Reduced-dose HPV vaccination effectiveness in post-vaccination surveillance studies: using mathematical modeling to quantify the impact of biases. IPVC8-0507. International Papillomavirus Conference. Sydney; 2018.
Brotherton JM, Budd A, Rompotis C, Bartlett N, Malloy MJ, Andersen RL, et al. Is one dose of human papillomavirus vaccine as effective as three?: A national cohort analysis. Papillomavirus Res 2019;8:100177.
Carozzi F, Puliti D, Ocello C, Anastasio PS, Moliterni EA, Perinetti E, et al. Monitoring vaccine and non-vaccine HPV type prevalence in the post-vaccination era in women living in the Basilicata region, Italy. BMC Infect Dis 2018;18:38.
Ferrara Health Agency. 2018 Results Assessment. 2019 Planning. Ferrara; 2019. Accessed 27 March 2019.
Organization for Economic Co-operation and Development. OECD.Stat - Health Care Utilization: Screening. 2018 [cited 8 July 2019]; Available from: https://stats.oecd.org/index.aspx?queryid=30159.
Nitsch D, Morton S, DeStavola BL, Clark H, Leon DA. How good is probabilistic record linkage to reconstruct reproductive histories? Results from the Aberdeen Children of the 1950s study. BMC Med Res Methodol 2006;22:15.
Castellsague X, Munoz N. Chapter 3: Cofactors in human papillomavirus carcinogenesis-role of parity, oral contraceptives, and tobacco smoking. JNCI Monographs 2003;2003:20-8.
Giambi C, Donati S, Carozzi F, Salmaso S, Declich S, Atti ML, et al. A cross-sectional study to estimate high-risk human papillomavirus prevalence and type distribution in Italian women aged 18-26 years. BMC Infect Dis 2013;7:74.
Markowitz LE, Drolet M, Perez N, Jit M, Brisson M. Human papillomavirus vaccine effectiveness by number of doses: Systematic review of data from national immunization programs. Vaccine 2018;36(32 Pt A):4806-15.
Gertig DM, Brotherton JM, Budd AC, Drennan K, Chappell G, Saville AM. Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study. BMC Med 2013;22:227.
Crowe E, Pandeya N, Brotherton JM, Dobson AJ, Kisely S, Lambert SB, et al. Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia. BMJ 2014;4:g1458.
Brotherton JML, Malloy M, Budd AC, Saville M, Drennan KT, Gertig DM. Effectiveness of less than three doses of quadrivalent human papillomavirus vaccine against cervical intraepithelial neoplasia when administered using a standard dose spacing schedule: Observational cohort of young women in Australia. Papillomavirus Res 2015;1:59-73.
Hofstetter AM, Ompad DC, Stockwell MS, Rosenthal SL, Soren K. Human papillomavirus vaccination and cervical cytology outcomes among urban low-income minority females. JAMA Pediatr 2016;170:445-52.
Kim J, Bell C, Sun M, Kliewer G, Xu L, McInerney M, et al. Effect of human papillomavirus vaccination on cervical cancer screening in Alberta. CMAJ 2016;188:E281-8.
Pollock KG, Kavanagh K, Potts A, Love J, Cuschieri K, Cubie H, et al. Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland. Br J Cancer 2014;111:1824-30.
Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356:1928-43.
Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009;374:301-14.
Wellings K, Collumbien M, Slaymaker E, Singh S, Hodges Z, Patel D, et al. Sexual behaviour in context: a global perspective. Lancet 2006;368:1706-28.
Giorgi Rossi P, Carozzi F, Federici A, Ronco G, Zappa M, Franceschi S. Cervical cancer screening in women vaccinated against human papillomavirus infection: Recommendations from a consensus conference. Prev Med 2017;98:21-30.
Palmer TJ, McFadden M, Pollock KGJ, Kavanagh K, Cuschieri K, Cruickshank M, et al. HPV immunisation and cervical screening -confirmation of changed performance of cytology as a screening test in immunised women: a retrospective population-based cohort study. Br J Cancer. 2016;114:582-9.
Restivo V, Costantino C, Fazio TF, Casuccio N, D'Angelo C, Vitale F, et al. Factors associated with HPV vaccine refusal among young adult women after ten years of vaccine implementation. Int J Environ Res Public Health 2018;15:770.
Fernández de Casadevante V, Gil Cuesta J, Cantarero-Arévalo L. Determinants in the uptake of the human papillomavirus vaccine: a systematic review based on European studies. Front Oncol 2015;5:141.
Giambi C. Assessment of regional decisions about the anti-HPV vaccination and first data on coverage at the end of the year 2009. Rome: Istituto Superiore di Sanità; 2010.
Chao C, Silverberg MJ, Becerra TA, Corley DA, Jensen CD, Chen Q, et al. Human papillomavirus vaccination and subsequent cervical cancer screening in a large integrated healthcare system. Am J Obstet Gynecol 2017;216:151.e1-9.
Zucchetto A, Ronco G, Giorgi Rossi P, Zappa M, Ferretti S, Franzo A, et al. Screening patterns within organized programs and survival of Italian women with invasive cervical cancer. Prev Med 2013;57:220-6.
Lonnberg S, Nieminen P, Luostarinen T, Anttila A. Mortality audit of the Finnish cervical cancer screening program. Int J Cancer 2013;132:2134-40.